SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiopharma Cred. Regulatory News (BPCR)

Share Price Information for Biopharma Cred. (BPCR)

Share Price is delayed by 15 minutes
Get Live Data
0.944    0.00 (0.00%)
Bid:
0.944
Ask:
0.946
Spread: 0.002 (0.212%)
Market Cap: $1.06b
BPCR Live PriceLast checked at - London Stock Exchange

Intraday Biopharma Cred. Share Chart

Dividend Declaration

19 Sep 2024 07:00

RNS Number : 7756E
BioPharma Credit PLC
19 September 2024
 

19 September 2024

 

BIOPHARMA CREDIT PLC 

("BIOPHARMA CREDIT" OR THE "COMPANY") 

ORDINARY AND SPECIAL DIVIDEND DECLARATION

3.79 CENT PER SHARE DISTRIBUTION INCLUDING A 2.04 CENT SPECIAL DISTRIBUTION

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the quarterly financial period ending 30 September 2024 of 3.75 cents per share. BPCR will also be declaring an interim dividend for the calendar year ending 31 December 2023 of 0.039155 cents per ordinary share to distribute the remaining revenue reserves for the calendar year 2023. Both interim dividends will be payable on 29 October 2024 to ordinary shareholders on the register as at 27 September 2024. The 3.789155 cents dividend comprises an ordinary dividend of 1.75 cents and a special dividend of 2.039155 cents. The ex-dividend date will be 26 September 2024.

The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share, enhanced by variable special dividends that comprise the excess earnings of the Company in 2024 thus far. After the payment of both interim dividends on 29 October 2024, dividends for the calendar year 2024 to date will total 7.289155 cents. 

The Company has chosen to designate the entire amount of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company.

The default payment for dividends is in US dollars. However, shareholders can elect to have dividends paid in sterling (GBP) and the option to elect a sterling dividend payment for this dividend will be available to shareholders until 27 September 2024 (the "Election Date").

Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST. Further details together with a copy of the Dividend Currency Election Form, which should be sent to Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL when completed, will be available on the Group's website shortly at www.bpcruk.com/investor-materials. CREST shareholders must elect via CREST.

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Samuel Adams

+44 (0) 20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVLPMPTMTABBII
Date   Source Headline
31st Oct 20233:30 pmRNSDirector Declaration
24th Oct 20237:00 amRNSUPDATE ON INVESTMENT
20th Oct 20234:00 pmRNSNet Asset Value(s) and Monthly Factsheet
12th Oct 20237:00 amRNSUPDATE ON INVESTMENT
2nd Oct 20231:32 pmRNSDirector/PDMR Shareholding
27th Sep 20237:00 amRNSHalf-year Report
26th Sep 202311:20 amRNSUPDATE ON INVESTMENT
22nd Sep 20234:00 pmRNSNet Asset Value(s) and Monthly Factsheet
19th Sep 20237:00 amRNSUpdate on Investment
31st Aug 20237:00 amRNSNotice of Half Year Results
29th Aug 202311:25 amRNSUpdate on Investment
23rd Aug 20234:30 pmRNSNet Asset Value(s) and Monthly Factsheet
10th Aug 20237:00 amRNSDividend Declaration
1st Aug 202311:29 amRNSTotal Voting Rights
31st Jul 20237:00 amRNSSTATEMENT RE REATA PHARMACEUTICALS
21st Jul 20234:00 pmRNSNet Asset Value(s)
21st Jul 202311:30 amRNSUPDATE ON INVESTMENT
18th Jul 20237:00 amRNSUPDATE ON INVESTMENT
11th Jul 20236:15 pmRNSTransaction in Own Shares
10th Jul 20236:15 pmRNSTransaction in Own Shares
3rd Jul 20231:34 pmRNSTotal Voting Rights
3rd Jul 20237:00 amRNSUpdate on Investment
30th Jun 20236:15 pmRNSTransaction in Own Shares
29th Jun 20236:15 pmRNSTransaction in Own Shares
26th Jun 20236:15 pmRNSTransaction in Own Shares
22nd Jun 20236:15 pmRNSTransaction in Own Shares
21st Jun 20234:00 pmRNSNet Asset Value(s)
20th Jun 20236:15 pmRNSTransaction in Own Shares
15th Jun 20236:15 pmRNSTransaction in Own Shares
13th Jun 20236:15 pmRNSTransaction in Own Shares
8th Jun 20236:15 pmRNSTransaction in Own Shares
8th Jun 20237:00 amRNSUPDATE ON INVESTMENT
7th Jun 20236:15 pmRNSTransaction in Own Shares
6th Jun 20236:15 pmRNSTransaction in Own Shares
1st Jun 202312:04 pmRNSTotal Voting Rights
31st May 20236:15 pmRNSTransaction in Own Shares
30th May 20233:08 pmRNSResult of AGM
26th May 20236:15 pmRNSTransaction in Own Shares
25th May 20236:15 pmRNSTransaction in Own Shares
24th May 20236:15 pmRNSTransaction in Own Shares
23rd May 20236:15 pmRNSTransaction in Own Shares
23rd May 20234:00 pmRNSNet Asset Value(s)
19th May 20236:15 pmRNSTransaction in Own Shares
19th May 20237:00 amRNSUpdate on Investment
18th May 20236:15 pmRNSTransaction in Own Shares
16th May 20233:40 pmRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSNEW INVESTMENT OF UP TO US$137.5 MILLION
9th May 20236:15 pmRNSTransaction in Own Shares
5th May 20236:15 pmRNSTransaction in Own Shares
2nd May 20236:15 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.